Journal
BMC RESEARCH NOTES
Volume 14, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1186/s13104-021-05700-x
Keywords
Migraine; Vascular cell adhesion molecule; Gene expression; Serum concentration; Omega-3; Nanocurcumin
Categories
Ask authors/readers for more resources
The study found that both omega-3 fatty acids (W-3 FAs) and the combination of W-3 and nanocurcumin can reduce serum levels and gene expression of VCAM in patients with episodic migraine. Nanocurcumin supplementation alone and the control group did not show significant changes.
Objective The purpose of this clinical trial was to examine the effect of omega-3 fatty acids (W-3 FAs), nanocurcumin and their combination on serum levels and gene expression of VCAM in patients with episodic migraine. Results In this study, 80 patients were randomly divided in to 4 groups to receive for 2 months. Both serum levels and gene expression of VCAM showed remarkable decreases after single W-3 and after combined W-3 and nanocurcumin interventions. However, a borderline significant change and no remarkable change were observed after single nanocurcumin supplementation and in control group, respectively. While a significant difference between study groups in VCAM concentrations existed, there was no meaningful difference in VCAM gene expression among groups. It appears that the W-3 and combined W-3 and nanocurcumin can relieve VCAM serum level and its gene expression in patients with episodic migraine. Moreover, the combination of W-3 with nanocurcumin might cause more significant declines in VCAM level in the serum of migraine patients than when W-3 is administered alone. Trial Registration: This study was registered in Iranian Registry of Clinical Trials (IRCT) with ID number: NCT02532023.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available